Skip to content

AOCI at other companies

Amgen logo
AmgenAMGN
-$190M+17.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$11.9M-59.1%
Immunome logo
ImmunomeIMNM
$0-100%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$699K-211%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$172K-553%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$494K-131%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's AOCI?
Replimune Group (REPL) reported AOCI of $5.56M in Q4 2025.
How has Replimune Group's AOCI changed year-over-year?
Replimune Group's AOCI decreased by 9.7% year-over-year, from $6.16M to $5.56M.
What is the long-term trend for Replimune Group's AOCI?
Over 4 years (2021 to 2025), Replimune Group's AOCI has grown at a 92.8% compound annual growth rate (CAGR), from -$394K to $5.45M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.